Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-06-06, Stock:NVS, The news for the past five days is as follows:
2019-05-30: NEWS1: Save the Date: 11 Biotech Stocks to Put on Your Radar.NEWS2: PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts.NEWS3: PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts.NEWS4: PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts.NEWS5: Bothered by the Price Tag of a $2.1 Million Drug? Read This Before Complaining Too Much.NEWS6: Bothered by the Price Tag of a $2.1 Million Drug? Read This Before Complaining Too Much.NEWS7: Health Care Sector Update for 05/30/2019: UBX, ACHV, NVS, JNJ, PFE, ABT, MRK, AMGN.NEWS8: Health Care Sector Update for 05/30/2019: UBX, ACHV, NVS, JNJ, PFE, ABT, MRK, AMGN.NEWS9: Bothered by the Price Tag of a $2.1 Million Drug? Read This Before Complaining Too Much.NEWS10: The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug.
2019-05-31: NEWS1: Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates.NEWS2: Nationwide Children's invented 'the most expensive drug ever,' but the hospital didn't set the price.NEWS3: FDA approval of life-saving Nationwide Children's invention bodes well for ongoing gene therapy research.NEWS4: Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?.NEWS5: Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?.NEWS6: Biogen Reports Interim Phase III Data on Diroximel Fumarate.NEWS7: Biogen Reports Interim Phase III Data on Diroximel Fumarate.NEWS8: Is the $2.1 Million Price Tag for Novartis&apos; Zolgensma Ridiculous?.NEWS9: Biogen Reports Interim Phase III Data on Diroximel Fumarate.NEWS10: Novartis (NVS) Reports Positive Phase III Data on Asthma Drug.NEWS11: Novartis (NVS) Reports Positive Phase III Data on Asthma Drug.NEWS12: Novartis (NVS) Reports Positive Phase III Data on Asthma Drug.
2019-06-03: NEWS1: Novartis (NVS) Announces Various Data Presentations at ASCO.NEWS2: Novartis (NVS) Announces Various Data Presentations at ASCO.NEWS3: Roche Presents Positive Data on Xolair & Updates From ASCO.NEWS4: Roche Presents Positive Data on Xolair & Updates From ASCO.NEWS5: Novartis (NVS) Announces Various Data Presentations at ASCO.NEWS6: Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO.NEWS7: Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO.NEWS8: Roche Presents Positive Data on Xolair & Updates From ASCO.NEWS9: Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO.NEWS10: Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials.
2019-06-04: NEWS1: It's Official: bluebird bio Gets a Green Light for Game-Changing Gene Therapy.NEWS2: It's Official: bluebird bio Gets a Green Light for Game-Changing Gene Therapy.NEWS3: Aduro Stock Crashes After ASCO Updates on Cancer Candidate.NEWS4: Aduro Stock Crashes After ASCO Updates on Cancer Candidate.NEWS5: Long-term Survival Benefit Shown for Metastatic Melanoma Patients Treated with Novartis Tafinlar® + Mekinist®.NEWS6: Aduro Stock Crashes After ASCO Updates on Cancer Candidate.
2019-06-05: NEWS1: Continued Smart M&A Moves Will Help Canopy Stock Break Out.NEWS2: Continued Smart M&A Moves Will Help Canopy Stock Break Out.NEWS3: Continued Smart M&A Moves Will Help Canopy Stock Break Out.

Answer: Rise